Fulcrum Therapeutics Inc
(NAS:FULC)
$
4.79
-0.05 (-1.03%)
Market Cap: 258.37 Mil
Enterprise Value: 12.97 Mil
PE Ratio: 0
PB Ratio: 1.00
GF Score: 50/100 Fulcrum Therapeutics Inc at Bank of America Healthcare Conference Transcript
May 12, 2022 / 06:20PM GMT
Release Date Price:
$7.57
(+5.14%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
Thanks, everybody. Welcome to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the senior SMID biotech analysts here at the bank. It's my pleasure to have our next presenting company, Fulcrum Therapeutics, with me. Sitting on stage are several members of the management team. We've got Bryan. We've got Judith. We've got Paul.
I'll let you introduce yourselves. And then maybe, Bryan, could you give us a couple of minute overview of the company, your platform and some of your key recent updates? And then we can go through into Q&A if that works.
Bryan E. Stuart
Fulcrum Therapeutics, Inc. - President, CEO & Director
Yes, absolutely. That would be great. So Bryan Stuart, the CEO of Fulcrum.
Judith A. Dunn;Paul Bruno
Fulcrum Therapeutics, Inc. - President of Research & Development;Fulcrum Therapeutics, Inc. -
I'm Judy Dunn, President of R&D.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot